Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS

Xing Zhang, Xiao-Ming Wang, Daria I. Vernikovskaya, Valentina Fokina, Tatiana Nanovskaya, Gary Hankins, Mahmoud Ahmed

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This report describes the development and validation of an LC-MS/MS method for the quantitative determination of glyburide (GLB), its five metabolites (M1, M2a, M2b, M3 and M4) and metformin (MET) in plasma and urine of pregnant patients under treatment with a combination of the two medications. The extraction recovery of the analytes from plasma samples was 87-99%, and that from urine samples was 85-95%. The differences in retention times among the analytes and the wide range of the concentrations of the medications and their metabolites in plasma and urine patient samples required the development of three LC methods. The lower limit of quantitation (LLOQ) of the analytes in plasma samples was as follows: GLB, 1.02 ng/mL; its five metabolites, 0.100-0.113 ng/mL; and MET, 4.95 ng/mL. The LLOQ in urine samples was 0.0594 ng/mL for GLB, 0.984-1.02 ng/mL for its five metabolites and 30.0 μg/mL for MET. The relative deviation of this method was <14% for intra-day and inter-day assays in plasma and urine samples, and the accuracy was 86-114% in plasma, and 94-105% in urine. The method described in this report was successfully utilized for determining the concentrations of the two medications in patient plasma and urine.

Original languageEnglish (US)
Pages (from-to)560-569
Number of pages10
JournalBiomedical Chromatography
Volume29
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Metabolites
Urine
Plasmas
Glyburide
Metformin
Glucovance
Assays
Recovery

Keywords

  • Gestational diabetes mellitus
  • Glyburide
  • LC-MS/MS
  • Metabolites
  • Metformin

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Pharmacology

Cite this

Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS. / Zhang, Xing; Wang, Xiao-Ming; Vernikovskaya, Daria I.; Fokina, Valentina; Nanovskaya, Tatiana; Hankins, Gary; Ahmed, Mahmoud.

In: Biomedical Chromatography, Vol. 29, No. 4, 01.04.2015, p. 560-569.

Research output: Contribution to journalArticle

@article{47f627669fa3469db49a4009585171d0,
title = "Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS",
abstract = "This report describes the development and validation of an LC-MS/MS method for the quantitative determination of glyburide (GLB), its five metabolites (M1, M2a, M2b, M3 and M4) and metformin (MET) in plasma and urine of pregnant patients under treatment with a combination of the two medications. The extraction recovery of the analytes from plasma samples was 87-99{\%}, and that from urine samples was 85-95{\%}. The differences in retention times among the analytes and the wide range of the concentrations of the medications and their metabolites in plasma and urine patient samples required the development of three LC methods. The lower limit of quantitation (LLOQ) of the analytes in plasma samples was as follows: GLB, 1.02 ng/mL; its five metabolites, 0.100-0.113 ng/mL; and MET, 4.95 ng/mL. The LLOQ in urine samples was 0.0594 ng/mL for GLB, 0.984-1.02 ng/mL for its five metabolites and 30.0 μg/mL for MET. The relative deviation of this method was <14{\%} for intra-day and inter-day assays in plasma and urine samples, and the accuracy was 86-114{\%} in plasma, and 94-105{\%} in urine. The method described in this report was successfully utilized for determining the concentrations of the two medications in patient plasma and urine.",
keywords = "Gestational diabetes mellitus, Glyburide, LC-MS/MS, Metabolites, Metformin",
author = "Xing Zhang and Xiao-Ming Wang and Vernikovskaya, {Daria I.} and Valentina Fokina and Tatiana Nanovskaya and Gary Hankins and Mahmoud Ahmed",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/bmc.3314",
language = "English (US)",
volume = "29",
pages = "560--569",
journal = "Biomedical Chromatography",
issn = "0269-3879",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Quantitative determination of metformin, glyburide and its metabolites in plasma and urine of pregnant patients by LC-MS/MS

AU - Zhang, Xing

AU - Wang, Xiao-Ming

AU - Vernikovskaya, Daria I.

AU - Fokina, Valentina

AU - Nanovskaya, Tatiana

AU - Hankins, Gary

AU - Ahmed, Mahmoud

PY - 2015/4/1

Y1 - 2015/4/1

N2 - This report describes the development and validation of an LC-MS/MS method for the quantitative determination of glyburide (GLB), its five metabolites (M1, M2a, M2b, M3 and M4) and metformin (MET) in plasma and urine of pregnant patients under treatment with a combination of the two medications. The extraction recovery of the analytes from plasma samples was 87-99%, and that from urine samples was 85-95%. The differences in retention times among the analytes and the wide range of the concentrations of the medications and their metabolites in plasma and urine patient samples required the development of three LC methods. The lower limit of quantitation (LLOQ) of the analytes in plasma samples was as follows: GLB, 1.02 ng/mL; its five metabolites, 0.100-0.113 ng/mL; and MET, 4.95 ng/mL. The LLOQ in urine samples was 0.0594 ng/mL for GLB, 0.984-1.02 ng/mL for its five metabolites and 30.0 μg/mL for MET. The relative deviation of this method was <14% for intra-day and inter-day assays in plasma and urine samples, and the accuracy was 86-114% in plasma, and 94-105% in urine. The method described in this report was successfully utilized for determining the concentrations of the two medications in patient plasma and urine.

AB - This report describes the development and validation of an LC-MS/MS method for the quantitative determination of glyburide (GLB), its five metabolites (M1, M2a, M2b, M3 and M4) and metformin (MET) in plasma and urine of pregnant patients under treatment with a combination of the two medications. The extraction recovery of the analytes from plasma samples was 87-99%, and that from urine samples was 85-95%. The differences in retention times among the analytes and the wide range of the concentrations of the medications and their metabolites in plasma and urine patient samples required the development of three LC methods. The lower limit of quantitation (LLOQ) of the analytes in plasma samples was as follows: GLB, 1.02 ng/mL; its five metabolites, 0.100-0.113 ng/mL; and MET, 4.95 ng/mL. The LLOQ in urine samples was 0.0594 ng/mL for GLB, 0.984-1.02 ng/mL for its five metabolites and 30.0 μg/mL for MET. The relative deviation of this method was <14% for intra-day and inter-day assays in plasma and urine samples, and the accuracy was 86-114% in plasma, and 94-105% in urine. The method described in this report was successfully utilized for determining the concentrations of the two medications in patient plasma and urine.

KW - Gestational diabetes mellitus

KW - Glyburide

KW - LC-MS/MS

KW - Metabolites

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=84925341807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925341807&partnerID=8YFLogxK

U2 - 10.1002/bmc.3314

DO - 10.1002/bmc.3314

M3 - Article

C2 - 25164921

AN - SCOPUS:84925341807

VL - 29

SP - 560

EP - 569

JO - Biomedical Chromatography

JF - Biomedical Chromatography

SN - 0269-3879

IS - 4

ER -